ASCO Genitourinary Cancers Symposium
ASCO GU 2022 Efficacy & Safety of Continuing Enza in Chemo-Naïve mCRPC Patients Treated With Docetaxel + Prednisolone Who Have Progressed on Enza: Phase 3b PRESIDE Study
By
ASCO Genitourinary Cancers Symposium
FEATURING
Axel Merseburger
By
ASCO Genitourinary Cancers Symposium
FEATURING
Axel Merseburger
Login to view comments.
Click here to Login